Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$17.76M$17.76Mderived+15.0% vs Q4 2020 Net Income-$5.33M-$5.33MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$10,868,000+15.4% Operating Incomederived-$5,316,000N/M Operating Cash Flowderived-$4,944,000N/M Margins · derivedGross margin61.2%+0.2 pt vs Q4 2020
Operating margin-29.9%+9.4 pt vs Q4 2020
Net margin-30.0%+9.5 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 14, 2022 · 73 d after period end